The many facets of liquid biopsies in lymphoma

The study from Meriranta et al1 in this issue of Blood details circulating tumor DNA analysis from 101 patients with large B-cell lymphomas undergoing first-line therapy on the Nordic LBC-05 trial. Using a custom capture-based sequencing approach, the authors assessed plasma cell-free DNA at time points before, during, and after immunochemotherapy. The investigators extensively analyze diverse features of tumor-derived cell-free DNA molecules, including quantitative measurements of tumor DNA, dynamic measurements during and after therapy, and mutational genotypes.

Automated summary

The study investigates circulating tumor DNA analysis in patients with large B-cell lymphomas undergoing first-line therapy, providing insights into the quantitative measurements, dynamic changes, and mutational genotypes of tumor-derived cell-free DNA during and after treatment.